Debra Yu, MDPresident and CBO at LianBio
Dr. Yu is currently President & CBO of LianBio, a company established in 2019 by Perceptive Advisors that is focused on bringing paradigm-shifting medicines to China and other major Asian markets. Previously, was most recently Managing Director and Head of Cross Border Healthcare Investment Banking at China Renaissance Securities (US) where she was instrumental in helping to build the firm’s strategic advisory and life science capital markets activities in the U.S. and China. Prior to that, she was Managing Director of Labrador Advisors, where she advised numerous cross-border partnerships and licensing transactions. Earlier, she was VP Strategy at WuxiApptec and helped to architect and co-lead Pfizer’s venture capital group. Dr. Yu was a bay area venture investor for several years, serving as General Partner of Delphi Ventures and Managing Director of Bay City Capital. She also held positions at McKinsey & Co. in New York and London. She began her career as an analyst at Morgan Stanley. Dr. Yu received a BA with high honors in Molecular Biology from Princeton University earned an MD from Harvard Medical School. She served as the Mid-Atlantic Regional Chairperson for Bayhelix for several years prior to serving on the Bayhelix Board in 2018-2019. Dr. Yu is also a Governor of the Asian American Alumni Association of Princeton University and an active supporter for the University’s Center for Contemporary China.